Baseline pain symptoms and quality of life scores related to uVIN were reported to be better following VeregenĀ® treatment
McGills pain questionnaire and DLQI questioners were used to assess changes in the symptoms of pain and quality of life (QoL) at each clinical visit. Baseline questionnaires were completed prior to starting treatment, and the scores from the questioners at each clinical visits were compared to baseline. Over 52 weeks, there was no discernible difference in pain symptoms and QoL score when compared to baseline in the placebo group. In the VeregenĀ® group, symptoms of pain were reported to be lower than baseline after patients completed 16 weeks of treatment and remained stable at 32 weeks follow up (Figure 2a). In the QoL index, there is a trend towards an improvement in QoL score in VeregenĀ® group after 16 weeks treatment and QoL scores, in general, has remained lower than baseline at 32 weeks (Figure 2b).